Immunotherapy
Immunotherapies continue to be a ‘revolution’
In 2016, the FDA approved the first immunotherapy for lymphoma. Since then, the field has exploded and now, just 4 years later, there are nine FDA-approved immunotherapy options for lymphoma, according to the Cancer Research Institute.
FDA clears investigational new drug application for ‘switchable’ CAR-T for B-cell malignancies
The FDA cleared an investigational new drug application for CLBR001 + SWI019 — a “switchable” chimeric antigen receptor T-cell therapy — for the treatment of relapsed or refractory B-cell malignancies, such as non-Hodgkin lymphoma and chronic lymphocytic leukemia, according to a press release issued by the agent’s manufacturer.
FDA grants priority review to Kite’s CAR-T for mantle cell lymphoma
The FDA granted priority review to the investigational chimeric antigen receptor T-cell therapy KTE-X19 for the treatment of adults with relapsed or refractory mantle cell lymphoma.
Foundation presents grants to six early career cancer researchers
Global longitudinal strain predicts CV risk in immune checkpoint inhibitor-related myocarditis
Patients with myocarditis related to immune checkpoint inhibitors and either a preserved or reduced ejection fraction had a reduced global longitudinal strain, according to a study published in the Journal of the American College of Cardiology.
FDA clears application for combination cell therapy for multiple myeloma
The FDA cleared an investigational new drug application for KP1237, a CD38-targeting antibody-recruiting molecule, in combination with autologous natural killer cells for the treatment of patients with multiple myeloma who previously underwent hematopoietic stem cell transplantation.
Pembrolizumab confers clinical benefit after previous treatments for small cell lung cancer
Pembrolizumab induced encouraging antitumor activity among a cohort of patients with recurrent or metastatic small cell lung cancer, according to a pooled analysis of data from the KEYNOTE-028 and KEYNOTE-158 studies published in Journal of Thoracic Oncology.
ASCO names refinement of surgical cancer treatment ‘Advance of the Year’
ASCO has named the refinement of surgical treatment of cancer as the Advance of the Year, recognizing emerging novel systemic therapies that changed the role of cancer surgery.
FDA approves Palforzia, first peanut allergy treatment for children
The FDA announced that it approved the oral immunotherapy Palforzia, the first treatment for peanut allergy in children aged 4 to 17 years.
Phase 3 trial of atezolizumab for urothelial cancer misses primary endpoint
Adjuvant atezolizumab failed to extend DFS compared with observation among patients with muscle-invasive urothelial cancer, according to topline results of a randomized phase 3 trial released by the agent’s manufacturer.